Related Experiment Video
Updated: Aug 7, 2026
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
Control of prostate cancer by transrectal HIFU in 227 patients
Laura Poissonnier1, Jean-Yves Chapelon, Olivier Rouvière
1Urology, Radiology and Pathology Department, Edouard Herriot Hospital, Lyon, France.
Purpose:
To evaluate the results of high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer with reference to disease-related prognostic factors.
Materials And Methods:
Patients with T1-2 localized prostate cancers, prostate specific antigen (PSA)
Results:
The study included 227 patients. Mean follow-up was 27+/-20 months (12-121 months). Eighty-six percent had negative control biopsies. Median nadir PSA was 0.10 ng/ml. The actuarial 5-year disease-free survival rate (DFSR), combining pathologic and biochemical outcomes, was 66%. DFSR showed a significant decrease when stratified according to initial PSA level: 90% with PSA
Conclusions:
HIFU for localized prostate cancer offered high control of local disease with low morbidity. The ability to repeat the HIFU treatment is of major interest.
